Claims for Patent: 8,425,900

Summary for Patent: 8,425,900

Title:	Method of delivering a protein into a cell
Abstract:	There is presently provided a complex of a micelle formed from a cationic polymer and a protein, and a method using the complex to deliver the protein into a cell.
Inventor(s):	Yang; Yi-Yan (Singapore, SG), Wang; Yong (Singapore, SG), Lee; Ashlynn Lingzhi (Singapore, SG)
Assignee:	Agency for Science, Technology and Research (Singapore, SG)
Application Number:	12/598,408
Patent Claims:	1. A micelle-protein complex comprising: a micelle of a cationic polymer, the cationic polymer having a structure of general formula I: --(W--X--Y--Z).sub.p--(W'--X'--Y'--Z').sub.q--; and a protein, the protein having a region available to complex with the micelle; the protein complexed to the exterior of the micelle via an interaction between the protein and the polymer; wherein, in general formula I: each of W, X, Y and Z is independently selected from ##STR00008## nothing, wherein only one of W, X, Y and Z is nothing and at least one of W, X, Y and Z is a group containing nitrogen bonded to R or R'; each of W', X', Y' and Z' is independently selected from ##STR00009## and nothing, wherein only one of W', X', Y' and Z' is nothing, and at least one of W', X', Y' and Z' is a group containing nitrogen bonded to R'' or R'''; each of R and R' is independently H, alkyl or heteroalkyl; each of R'' and R''' is independently a hydrophobic group; each of p and q is independently an integer greater than zero; and each of m, n, r, s, t, m', n', r', s' and t' is independently an integer greater than 0. 2. The micelle-protein complex according to claim 1, wherein the region of the protein available to complex with the micelle is a negatively charged region. 3. The micelle-protein complex according to claim 1, wherein the cationic polymer comprises poly{N-methyldietheneamine sebacate)-co-[(cholesteryl oxocarbonylamido ethyl)methyl bis(ethylene)ammonium bromide]sebacate}. 4. The micelle-protein complex according to claim 1, wherein the protein is an oligopeptide, a peptide, a polypeptide, a full length protein, a protein fragment, a protein domain, or a fusion protein. 5. The micelle-protein complex according to claim 1, wherein the protein is biologically active. 6. The micelle-protein complex according to claim 5, wherein the protein comprises a hormone, a receptor ligand, a transcription factor, a transcription enhancer, a transcription suppressor, an enzyme, a kinase, a phosphatase, a nuclease, a protease, a growth factor, an antibody, or a cytotoxic protein. 7. The micelle-protein complex according to claim 6 wherein the growth factor comprises Glial-derived neurotropic factor, the cytotoxic protein comprises lectin A, and the antibody comprises herceptin. 8. The micelle-protein complex according to claim 1, further comprising an additional therapeutic agent. 9. The micelle-protein complex according to claim 8, wherein the additional therapeutic agent is a pharmaceutical agent included in the interior of the micelle. 10. The micelle-protein complex according to claim 8, wherein the additional therapeutic agent is a pharmaceutical agent or a nucleic acid molecule complexed to the exterior of the micelle. 11. A method of delivering a protein into a cell comprising: contacting the micelle-protein complex according to claim 1 with a cell so that the micelle-protein complex is taken up into the cell. 12. The method according to claim 11, wherein the cell is in vitro. 13. The method according to claim 12, wherein the cell is in vivo and the method comprises administering the micelle-protein complex to a subject. 14. The method according to claim 13, wherein the subject is a human. 15. The method according to claim 11, wherein the protein is biologically active and retains biological activity after delivery into the cell. 16. A pharmaceutical composition comprising the micelle-protein complex according to claim 1. 17. The pharmaceutical composition according to claim 16, further comprising a pharmaceutically acceptable carrier. 18. The micelle-protein complex according to claim 4, wherein the protein is biologically active. 19. The micelle-protein complex according to claim 5, further comprising an additional therapeutic agent. 20. The pharmaceutical composition according to claim 16 comprising the micelle-protein complex according to claim 5. 21. The micelle-protein complex according to claim 1, wherein the region of the protein available to complex with the micelle is a polar region. 22. The micelle-protein complex according to claim 1, wherein the region of the protein available to complex with the micelle is a hydrophobic region.

Details for Patent 8,425,900

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-04-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-04-30